AB Science Completes Private Placement, Raising EUR 3.2 Million
Biopharmaceutical company AB Science has successfully closed a private placement, raising EUR 3.2 million. The funds are intended to support the company's ongoing clinical development programs.
Paris-based biopharmaceutical company AB Science announced on Wednesday the successful completion of a private placement, raising EUR 3.2 million. The company did not disclose specific details regarding the investors or the precise allocation of the funds.
The capital raised is designated to bolster AB Science's development pipeline, with a particular emphasis on advancing the clinical studies of its drug candidates. The company is developing several potential therapies, including masitinib, for a range of conditions such as amyotrophic lateral sclerosis (ALS), sickle cell disease, and certain cancers.
AB Science has previously navigated complex funding landscapes and clinical trial progressions. This successful financing round could provide crucial resources and stability for its ongoing research initiatives.
The company continues to focus on the progression of masitinib through clinical trials across various therapeutic areas, aiming to bring new treatment options to patients.